Opaleye Management Inc. Files Schedule 13G for Karyopharm Therapeutics Inc.

Opaleye Management Inc., along with Opaleye, L.P. and James Silverman, filed a Schedule 13G with the SEC on October 17, 2025, disclosing beneficial ownership of 1,569,002 shares of Karyopharm Therapeutics Inc. common stock, representing 9.48% of the outstanding shares. The shares include 619,089 issuable upon exercise of immediately exercisable warrants. The filing is made pursuant to Rule 13d-1(c) and includes a Joint Filing Agreement among the reporting persons. The filing certifies that the securities were not acquired for the purpose of influencing the control of the issuer.